Dr. Reddy's Labs RDY

NYS: RDY | ISIN: US2561352038 13/05/2025

14,10 USD (+1,22%)

(+1,22%) 13/05/2025

Grafiek Dr. Reddy's Laboratories Ltd.

Grafiek Dr. Reddy's Laboratories Ltd.

1 dag1d 1,22%
1 week1w 4,29%
1 maand1m 6,42%
3 maanden3m 3,68%
6 maanden6m -0,98%
1 jaar1j -79,76%
5 jaar5j -72,01%

Dr. Reddy's Laboratories Ltd. in het nieuws

Toon enkel gratis nieuws

27 maart 2025 · Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia · Persbericht

7 september 2021 · Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications · Persbericht

3 juni 2021 · Global Response Aid Reports Midyear Sales Results for COVID Drug · Persbericht

3 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY · Persbericht

19 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY · Persbericht

2 februari 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY · Persbericht

Profiel Dr. Reddy's Laboratories Ltd.

Farmaceutische Producten: Generisch

Gezondheidstechnologie

Medicinale en botanische productie

CEO: G. Prasad

Werknemers: 24.795

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe